Korman, N., K. Papp, J. . Bagel, P. Foley, A. Morita, S. Banerjee, E. Colston, T. Wang, J. Throup, and D. Thaci. “Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 5, no. 6, Nov. 2021, p. s39, doi:10.25251/skin.5.supp.39.